Abacavir sulfate 50 mg | 100.00%
TargetMol
Abacavir, a nucleoside analogue, effectively utilize its antiviral activity
More Information Supplier PageAbacavir sulfate
Search Results
Abacavir sulfate 10 mg | 100.00%
TargetMol
Abacavir, a nucleoside analogue, effectively utilize its antiviral activity
More Information Supplier PageAbacavir sulfate
Enalaprilat Dihydrate 50 mg | 99.78%
TargetMol
Enalaprilat Dihydrate (MK-422 Dihydrate) （IC50=1.94 nM） is a potent angiotensin-converting enzyme (ACE) inhibitor.
More Information Supplier PageEnalaprilat Dihydrate
Enalaprilat Dihydrate 100 mg | 99.78%
TargetMol
Enalaprilat Dihydrate (MK-422 Dihydrate) （IC50=1.94 nM） is a potent angiotensin-converting enzyme (ACE) inhibitor.
More Information Supplier PageEnalaprilat Dihydrate
Bosentan 50 mg | Purity Not Available
TargetMol
Bosentan is a sulfonamide-derived, competitive and specific endothelin receptor antagonist with a slightly higher affinity for the endothelin A receptor than endothelin B receptor. Bosentan blocks the action of endothelin 1, an extremely potent endogenous vasoconstrictor and bronchoconstrictor, by binding to endothelin A and endothelin B receptors in the endothelium and vascular smooth muscle. Bosentan […]
More Information Supplier PageBosentan
Bosentan 200 mg | Purity Not Available
TargetMol
Bosentan is a sulfonamide-derived, competitive and specific endothelin receptor antagonist with a slightly higher affinity for the endothelin A receptor than endothelin B receptor. Bosentan blocks the action of endothelin 1, an extremely potent endogenous vasoconstrictor and bronchoconstrictor, by binding to endothelin A and endothelin B receptors in the endothelium and vascular smooth muscle. Bosentan […]
More Information Supplier PageBosentan
Bosentan 100 mg | Purity Not Available
TargetMol
Bosentan is a sulfonamide-derived, competitive and specific endothelin receptor antagonist with a slightly higher affinity for the endothelin A receptor than endothelin B receptor. Bosentan blocks the action of endothelin 1, an extremely potent endogenous vasoconstrictor and bronchoconstrictor, by binding to endothelin A and endothelin B receptors in the endothelium and vascular smooth muscle. Bosentan […]
More Information Supplier PageBosentan
Onvansertib 5 mg | 97.01%
TargetMol
Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3.
More Information Supplier PageOnvansertib
Onvansertib 50 mg | 97.01%
TargetMol
Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3.
More Information Supplier PageOnvansertib
Onvansertib 10 mg | 97.01%
TargetMol
Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3.
More Information Supplier PageOnvansertib